Qyuns Therapeutics Invests RMB270 Million in Low-Risk PDB Wealth Products

Qyuns Therapeutics Co., Ltd. Class H ( (HK:2509) ) just unveiled an update.

Qyuns Therapeutics has entered into a series of new subscription agreements with PDB to deploy idle funds into low-risk, principal-guaranteed floating-yield structured deposit products. The company will invest a combined RMB270 million across three Liduoduo Corporate Stable Profit products, with staggered maturities between August and November 2026 and guaranteed annual yields ranging from 0.70% to 0.95%.

The board said pricing was set on normal commercial terms after arm’s-length negotiations, reflecting available surplus cash, expected returns and prevailing market interest rates. The subscriptions will be funded entirely from the company’s own resources excluding IPO proceeds, underscoring a conservative treasury strategy aimed at enhancing returns on idle cash without materially increasing risk.

More about Qyuns Therapeutics Co., Ltd. Class H

Qyuns Therapeutics Co., Ltd. is a Hong Kong-listed company incorporated in mainland China that operates in the biopharmaceutical sector. The group focuses on developing and commercializing therapeutic products, and actively manages surplus liquidity to support its capital efficiency and financial stability.

Average Trading Volume: 285,239

Technical Sentiment Signal: Sell

Current Market Cap: HK$4.03B

For a thorough assessment of 2509 stock, go to TipRanks’ Stock Analysis page.